Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing tradition and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "medicine health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] - Financial returns from investments in Guangfa Securities contributed 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024 respectively, providing continuous financial support for the pharmaceutical business [3] Group 2: Financial Empowerment - The financial layout allows Jilin Aodong to maintain stable and abundant returns, which are reinvested into the pharmaceutical sector to alleviate the high risks and long cycles of research and development [3] - The company emphasizes a principle of "main business first, financial empowerment," ensuring that financial gains are directed back to support the core pharmaceutical operations [3] Group 3: Technological Innovation - Jilin Aodong places technological innovation at the core of its strategy, focusing on the research of key raw materials and advancing in fields like anti-aging and regenerative medicine [5] - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of deer antler, ensuring the quality and traceability of raw materials [5][6] - The implementation of modern technology in traditional practices is seen as essential for unlocking the core value of traditional Chinese medicine [5][6] Group 4: Industry Development - The modernization of traditional Chinese medicine is supported by national policies aimed at enhancing quality, digital transformation, and new drug development [4] - Jilin Aodong aims to reshape production factors through technological innovation, transitioning from resource-dependent to innovation-driven models [6] - The company is committed to continuous investment in research and development, enhancing its intelligent layout across the entire industrial chain, and maintaining its heritage as a time-honored brand [7]

Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing heritage and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "pharmaceutical health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] Group 2: Financial Performance - In 2023 and 2024, the investment in Guangfa Securities is expected to contribute 1.243 billion and 1.749 billion yuan in revenue, respectively, with a total of 8.757 billion yuan in cash dividends provided to the company [3] - Financial returns are reinvested into the pharmaceutical business, alleviating the high risks and long cycles associated with research and development [3] Group 3: Technological Innovation - The modernization of traditional Chinese medicine relies on modern technology to unlock its core value, transitioning from "experience inheritance" to "scientific decoding" [4] - Jilin Aodong focuses on core material research and is actively involved in cutting-edge fields such as anti-aging and regenerative medicine [4][5] Group 4: Production and Quality Control - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of its core product, the Aodong deer antler [4][6] - Investments exceeding 46 million yuan have been made to upgrade disease prevention facilities and implement a digital quality control system across its standardized breeding bases [6] Group 5: Future Outlook - Jilin Aodong aims to deepen its dual-driven advantages and integrate new productive forces throughout its industrial development process, focusing on continuous investment in research and intelligent layout [7]

证券代码：600713 证券简称：南京医药 编号：ls2026-001 债券代码：110098 债券简称：南药转债 南京医药集团股份有限公司 经中国证券监督管理委员会《关于同意南京医药股份有限公司向不特定对象 发行可转换公司债券注册的批复》（证监许可〔2024〕1736 号）核准，公司向 不特定对象发行可转债 10,814,910 张，每张面值为 100 元，发行总额为 108,149.10 万元。票面利率为第一年 0.20%、第二年 0.40%、第三年 0.60%、第四年 1.50%、 第五年 1.80%、第六年 2.00%。本次发行的可转债存续期限为自发行之日起六年 （2024 年 12 月 25 日至 2030 年 12 月 24 日）。 经《上海证券交易所自律监管决定书》（〔2025〕11 号）同意，公司本次 发行的可转债于 2025 年 1 月 20 日起在上海证券交易所挂牌交易，债券简称为"南 药转债"，债券代码为"110098"。 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ...

Core Viewpoint - The traditional Chinese medicine industry is currently in a significant development opportunity period, and the company aims to leverage policy and market opportunities to innovate and grow within this sector [1] Group 1: Strengthening Traditional Chinese Medicine Industry - The company originated from a state-owned deer farm and has established a standardized breeding base for Sika deer, ensuring high-quality raw materials for traditional Chinese medicine [1][2] - The company has invested over 46 million yuan in upgrading epidemic prevention facilities, maintaining a zero-positive record for brucellosis and tuberculosis since 2021 [1][2] - The company has obtained 525 registration certificates in the Chinese medicine granule sector, enhancing its influence in industry standards [2] Group 2: Research and Development Innovation - The company focuses on core material research and has increased investment in technology development, transitioning from experience-based practices to scientific decoding [2][4] - The company has developed a product cluster centered around Sika deer, including various medicinal products, creating an ecological closed loop from breeding to pharmaceutical products [2][3] - The company emphasizes the integration of research, breeding, processing, and market feedback to drive fundamental changes in production methods [4] Group 3: Financial and Capital Interaction - The company has adopted a dual-driven development model of "healthcare + financial capital," using financial resources to support long-term research and development [5][6] - The company is the largest shareholder of Guangfa Securities, which has provided significant cash flow and stability, contributing 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024, respectively [6] - The company collaborates with various universities and research institutions to enhance its research capabilities and invest in promising biopharmaceutical projects [6][7]

Market Overview - The pharmaceutical commercial sector declined by 0.69% on December 31, with Luyuan Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 23.60, up 2.61% with a trading volume of 41,600 shares and a transaction value of 97.15 million [1] - Nanjing Pharmaceutical (600713) closed at 5.46, up 1.49% with a trading volume of 197,800 shares and a transaction value of 107 million [1] - Run Da Medical (603108) closed at 14.95, up 0.88% with a trading volume of 103,700 shares and a transaction value of 155 million [1] - Other notable stocks include Liuyuan Group (603368) at 17.82, up 0.62%, and China Pharmaceutical (600056) at 10.33, up 0.29% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 781 million from institutional investors, while retail investors saw a net inflow of 762 million [2] - The main capital inflow and outflow for selected stocks include: - Huaren Health (301408) with a net inflow of 83.36 million from institutional investors [3] - Shanghai Pharmaceutical (601607) with a net inflow of 22.40 million from institutional investors [3] - Yifeng Pharmacy (603939) with a net inflow of 19.37 million from institutional investors [3]

Core Insights - The Guangzhou Pharmaceutical Group is accelerating its transformation into a technology-driven and innovative enterprise, with a focus on modernization, digitalization, technological advancement, and internationalization during the 14th Five-Year Plan period [2][3] Investment and Innovation Strategy - The company plans to invest between 100-150 billion yuan in research and development and 200-300 billion yuan in industrial investment and acquisitions during the 14th Five-Year Plan [3][4] - The strategy includes building incubation platforms, enhancing innovation ecosystems, and optimizing incentives to achieve the goal of becoming a world-class pharmaceutical and health technology innovation enterprise [3][4] Expert Collaboration - Over 30 experts, including three academicians, have been appointed to form an advisory "brain" for the company's innovation efforts, emphasizing the importance of scientific insight and advanced technology platforms in modern pharmaceutical innovation [4][6] Innovation Platforms - The company has established seven major innovation platforms, including Traditional Chinese Medicine, chemical drugs, biological drugs, high-end nutrition, nuclear medicine, animal health, and medical devices, to strengthen its innovation capabilities [8] - The platforms aim to facilitate the transition from laboratory research to production, addressing the "last mile" challenge in drug development [8] Strategic Partnerships - More than 20 cooperation projects were signed at the conference, including strategic collaborations with Muen Bio, Data Science Group, Huawei Technologies, and various universities to enhance digital development and promote the application of microbiological technologies [9]

Core Viewpoint - A total of 292 listed companies have participated in the establishment of 340 industrial merger and acquisition funds in 2023, with 183 funds completed and 4 halted, indicating a strong trend towards investment in cutting-edge technology and strategic economic sectors to drive innovation and transformation [1] Group 1: Company Initiatives - Nanjing Pharmaceutical Group Co., Ltd. plans to invest 119.8 million yuan, accounting for 59.9% of the total subscription amount, in a new merger and acquisition fund focused on medical devices [1] - The company's "14th Five-Year" strategic plan emphasizes integration into the "Healthy China" initiative, focusing on the health industry and extending the existing industrial chain to explore new spaces for innovation and transformation [2] Group 2: Benefits of Establishing Funds - Establishing industrial merger and acquisition funds allows companies to strategically layout their industrial chains, achieve business synergies, and seize early advantages in innovation [2] - Companies can leverage financial effects by using a small amount of their own funds to attract more social capital, significantly reducing the direct cash flow impact of large-scale mergers [2] - The financial performance can be optimized as costs and risks during the project incubation phase typically do not need to be included in the listed company's financial statements, smoothing out performance fluctuations [2] Group 3: Considerations and Compliance - Companies must ensure strategic alignment with their core business and avoid speculative investments that deviate from their main operations [3] - It is crucial to establish a robust governance structure for the funds to maintain control and prevent conflicts of interest and hasty decision-making [3] - Compliance with information disclosure is essential, including timely updates on fund establishment, investment progress, and related transactions to avoid insider trading and regulatory risks [3]

白云山公告称，截至2025年前三季度，其营收同比增4.31%，净利润同比增4.78%。公司聚焦主业，推 进产业链上中下游发展，优化采购与数字化转型。投资并购方面，广药二期基金7.49亿元收购南京医药 11.04%股份，广州医药5亿元竞得浙江省医药工业100%股权等。创新上，1-11月新增国家级平台等，新 增27个新产品开发项目。分红上，2024年分红13.01亿元，占比45.87%；2025年上半年分红6.5亿元，占 比22.93%。公司还在信息披露、社会责任、公司治理等方面积极作为。 ...

Core Viewpoint - Nanjing Pharmaceutical Group Co., Ltd. plans to establish a subsidiary investment company focused on the medical device sector, with a significant investment from the company itself, aimed at enhancing its strategic positioning in the industry [1][2]. Group 1: Investment Structure - Nanjing Pharmaceutical will invest approximately 120 million yuan, accounting for 59.9% of the total registered capital of the new investment company [1]. - The investment company will be set up in collaboration with Nanjing New Industry Investment Management Co., Ltd. and Nanjing New Industry Medical Health Strong Chain M&A Equity Investment Fund [1]. Group 2: Target Investment - The newly formed investment company will specifically target an investment in Ningbo Jiangfeng Biological Information Technology Co., Ltd., acquiring approximately 22.5% of its equity, with a total valuation not exceeding 750 million yuan [2]. - Jiangfeng Biological, established in 2011, specializes in digital pathology and is recognized as a national high-tech enterprise focusing on innovative pathology diagnostics [2]. Group 3: Strategic Implications - The investment strategy reflects a model of "core enterprise + state-owned fund + industry chain target," which is expected to accelerate the transformation of technological achievements and promote innovation in the digital pathology field [2]. - This approach serves as a replicable example for local industrial development, encouraging collaboration between core enterprises and state-owned funds to enhance competitiveness and drive industrial upgrades [2].

Core Viewpoint - The company is actively expanding its presence in the East China commercial market through strategic acquisitions and internationalization efforts [2][3]. Group 1: Acquisition of Zhejiang Medical Industry - The company announced that its subsidiary, Guangzhou Pharmaceutical, plans to acquire 100% equity of Zhejiang Medical Industry from Haizheng Pharmaceutical for a total consideration of 501 million yuan [1]. - Zhejiang Medical Industry is ranked among the top six pharmaceutical distribution companies in Zhejiang Province, with projected revenues of 4.245 billion yuan for 2024 and 2.920 billion yuan for the first quarter of 2025 [2]. - This acquisition is expected to enhance Guangzhou Pharmaceutical's customer network in Zhejiang and surrounding areas, optimizing its industrial layout in East China and improving market coverage [2]. Group 2: Investment in Nanjing Pharmaceutical - The company announced an investment in Nanjing Pharmaceutical through its subsidiary, Guangyao Phase II Fund, to acquire a portion of its shares by September 2025 [2]. - This investment aims to strengthen business cooperation with Nanjing Pharmaceutical, enhancing collaboration in capital, distribution channels, and traditional Chinese medicine, thereby optimizing the industrial layout in East China [2]. Group 3: Internationalization of Health Sector - In 2025, the company plans to accelerate the internationalization of its health sector, launching four international flavors in a global event in Shanghai [3]. - The international flavors have been gradually launched in countries like Singapore and Malaysia since November, and a local production cooperation framework has been signed with partners in Malaysia [3]. - The company is transitioning from product export to industry chain export and brand export, indicating a significant upgrade in its international strategy [3]. Group 4: Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 3.12 billion yuan and 3.431 billion yuan, respectively [3]. - The current A-share price corresponds to a price-to-earnings ratio of 13.4 and 12.2 for 2025 and 2026, while the H-share price corresponds to 8.8 and 7.9 [3]. - The company maintains a target price of 34.0 yuan for A-shares and 23.0 HKD for H-shares, indicating potential upside of 32.5% and 24.7%, respectively [3].